What the results of Wegovy’s longest clinical trial yet show about ...
WEBMay 13, 2024 · CNN — New analyses of the longest clinical trial yet of the weight-loss drug Wegovy are shedding light on how quickly it helps people lose weight, how long they sustain that weight loss and how...
FDA Approves First Treatment to Reduce Risk of Serious Heart …
WEBToday, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults...
FDA Approves New Drug Treatment for Chronic Weight …
WEBFDA approves Wegovy (semaglutide) injection for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
Weight-loss drug Wegovy produces ‘largest benefit ever seen’ for ...
WEBAug 25, 2023 · A study found that a 2.4-milligram weekly dose of semaglutide, sold as Wegovy for weight loss, led to an improvement of 17 points on a 100-point scale that’s used to assess symptoms of a...
Wegovy Approved By FDA to Reduce Heart Attack Risk - The New York Times
WEBMar 11, 2024 · Wegovy, the blockbuster weight loss drug, is now approved for a new use: reducing the risk of heart attacks, strokes and cardiovascular-related death in adults who have heart disease and are...
Obesity drug Wegovy cut risk of serious heart ... - Associated Press News
WEBNov 11, 2023 · A new large study finds that the popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in certain patients. The international trial showed the weekly injections prevented heart attacks, strokes and heart-related deaths.
News details - Novo Nordisk
WEBMar 8, 2024 · Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity. Wegovy® (semaglutide) injection 2.4 mg is the first-and-only medicine indicated for both reduction of the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke and for long-term ...
Novo Nordisk A/S: Wegovy® recommended by the European
WEB1 day ago · About Wegovy ® (semaglutide 2.4 mg) In the EU, Wegovy ® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m ...
Wegovy Cuts Risk of Heart Problems, Novo Nordisk Trial Says
WEBAug 8, 2023 · A new obesity drug, Wegovy, slashed the risk of serious heart problems by 20 percent in a large trial, the drug’s maker said on Tuesday, a finding that could challenge the perception of...
News Details - Novo Nordisk
WEBMar 8, 2024 · The approval is based on the SELECT cardiovascular outcomes trial, which demonstrated that Wegovy ® statistically significantly reduced the risk of MACE by 20% compared to placebo when added to standard of care. The exact mechanism of cardiovascular risk reduction has not been established.
- Some results have been removed
Skip to content